Formulations with improved bioavailability

By combining amorphous TML-6 with excipients to form an improved curcumin formulation, the problem of low bioavailability of curcumin is solved and its efficacy in treating neurodegenerative diseases is significantly improved.

CN118892476APending Publication Date: 2024-11-05MERRY LIFE BIOMEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410550310.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-06
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The low bioavailability and rapid metabolism of curcumin hinder its application in the treatment of human diseases, especially in neurodegenerative diseases.

Method used

Develop a formulation comprising amorphous TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof and in combination with one or more excipients, including based on polymethacrylates The copolymers, poloxamer and cellulose derivatives form improved solubility and bioavailability through improved solvent systems and preparation methods.

Benefits of technology

It improves the solubility and bioavailability of curcumin, extends its in vivo half-life, and significantly improves its therapeutic effect on neurodegenerative diseases, liver diseases, cardiovascular diseases, obesity, inflammatory diseases and aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118892476A_ABST
    Figure CN118892476A_ABST
Patent Text Reader

Abstract

A formulation comprising TML-6 in amorphous form or pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more excipients # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 500,094, filed on May 4, 2023, which is incorporated herein by reference. Technical Field

[0003] The invention of the present disclosure relates to a formulation comprising a curcumin derivative. More specifically, the present disclosure relates to an oral formulation comprising a curcumin derivative having improved solubility, bioavailability and / or PK profile. Background Art

[0004] Curcumin is the main component of turmeric (Curcumin longa; commonly known as turmeric), a perennial plant belonging to the ginger family that grows naturally in India and other parts of Asia. Curcumin effectively protects against a variety of diseases, such as cancer, cardiovascular disease, obesity, liver disease, inflammatory diseases and aging. Although a series of epidemiological surveys, animal experiments and cell line studies have shown the beneficial effects of curcumin, the low bioavailability and rapid metabolism of curcumin have hindered the therapeutic development of curcumin for human diseases [Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM: Comparative absorption of curcumin formulations, Nutr J 2014, 13: 11]. Summary of the invention

[0005] The present disclosure presents formulations comprising Curcumin derivatives for use in the treatment and / or prevention of neurodegenerative diseases, said formulations having improved solubility and bioavailability and / or PK profiles.

[0006] The present disclosure provides a formulation comprising amorphous TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more excipients.

[0007]

[0008] In one embodiment, the formulation is characterized in that a differential scanning calorimetry thermogram does not contain any sharp endothermic peaks.

[0009] In one embodiment, the formulation is characterized in that the DSC thermogram does not comprise an endothermic peak corresponding to crystalline TML-6.

[0010] In one embodiment, the formulation is characterized in that the DSC thermogram comprises a broad endothermic peak at about 50°C to about 90°C.

[0011] In one embodiment, the formulation is characterized by an X-ray powder diffraction (XRPD) pattern that is substantially continuous and devoid of sharp, narrow diffraction peaks.

[0012] In one embodiment, the formulation is characterized in that the XRPD pattern does not include 2θ reflection angles of one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3° (±0.2° 2θ).

[0013] The present disclosure further provides a formulation comprising about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 80% (w / w) of one or more excipients,

[0014]

[0015] In one embodiment, the TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof is in an amorphous form.

[0016] In one embodiment, the formulation comprises about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

[0017] In one embodiment, the one or more excipients comprise an enteric polymer.

[0018] In one embodiment, the one or more excipients include at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer and / or a cellulose derivative excipient.

[0019] In one embodiment, the ratio of the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer to the cellulose derivative excipient is in the range of about 1:5 to about 5:1.

[0020] In one embodiment, the amount of the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer is in the range of about 10% to about 70% (w / w), and the amount of the cellulose derivative excipient is in the range of about 10% to about 70% (w / w).

[0021] In one embodiment, the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer is selected from the group consisting of: poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2; polymers of methyl acrylate, methyl methacrylate and methacrylic acid; poly(butyl methacrylate-co-(2-dimethylaminoethyl methacrylate); 1:2:1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) -trimethylammoniumethyl ester chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2 :0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate) 2:1 containing 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether) and poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether) and their combinations.

[0022] In one embodiment, the cellulose derivative excipient is selected from the group consisting of: cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropyl methylcellulose phthalate, microcrystalline cellulose, hydroxyethyl cellulose and hydroxypropyl methylcellulose.

[0023] In one embodiment, the formulation is in the form of tablets, granules, capsules or spray-dried powders.

[0024] The present disclosure also provides a pharmaceutical composition comprising the formulation and one or more additional excipients.

[0025] In one embodiment, the one or more additional excipients include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.

[0026] The present disclosure further provides a method for preventing and / or treating neurodegenerative diseases, liver diseases, cancer, cardiovascular diseases, obesity, inflammatory diseases or aging in a subject in need of such treatment, comprising administering the formulation or the pharmaceutical composition to the subject.

[0027] In one embodiment, the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, or a prion disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 The X-ray powder diffraction (XRPD) pattern of TML-6 is shown.

[0029] Figure 2 The XRPD pattern of TML-6 Formulation E13 is shown.

[0030] Figure 3 Shown are the DSC thermograms of TML-6 and TML-6 formulations E14 to E17.

[0031] Figure 4 Shown are the DSC thermograms of TML-6 and TML-6 formulation E04.

[0032] Figure 5Shown are the DSC thermograms of TML-6 and TML-6 formulations E10 and E12.

[0033] Figure 6 Shown are the plasma concentration-time curves (mean values) of TML-6 in rats from 0 to 10 hours after a single administration of TML-6 and TML-6 formulations E02, E10, E12, and E13.

[0034] Figure 7 Shown are the plasma concentration-time curves (mean values) of TML-6 in rats from 0 to 24 hours after a single administration of TML-6 and TML-6 formulations E02, E10, E12, and E13. DETAILED DESCRIPTION

[0035] By referring to the following detailed description of various embodiments of the present invention, examples and chemical diagrams and tables and their related descriptions, the present invention can be more easily understood. It should be understood that unless the claims specifically indicate otherwise, the present invention is not limited to a specific preparation method, carrier or formulation, or is not limited to the specific mode of the compound of the present invention being formulated as a product or composition intended for topical, oral or parenteral administration, because such things can certainly be changed as those of ordinary skill in the relevant field fully understand. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments, and are not intended to be restrictive.

[0036] In this application, terms such as "a", "an", and "the" are not intended to refer to only a single entity, but include general categories, which can be illustrated using specific examples. The terms "a", "an", and "the" can be used interchangeably with the term "at least one". The phrases "at least one" and "comprising at least one" following a list refer to any one of the items in the list and any combination of two or more items in the list. Unless otherwise stated, all numerical ranges include their endpoints and non-integer values ​​between the endpoints.

[0037] As used herein, the term "subject" means any animal, preferably a mammal, and more preferably a human. Examples of subjects include humans, non-human primates, rodents, guinea pigs, rabbits, sheep, pigs, goats, cattle, horses, dogs, and cats.

[0038] As used herein, the terms "treating" or "treatment" means reversing, alleviating, inhibiting the progression of, or ameliorating the disorder, disease, or condition to which such terms apply, or one or more symptoms of such disorder, disease, or condition.

[0039] The term "polymer" refers to a molecule whose structure comprises the multiple repetition of units derived actually or conceptually from molecules of relatively lower molecular weight.

[0040] The term "solvent" refers to a homogeneous liquid material, which may be a single compound or a combination of compounds, and which may or may not include water.

[0041] As used herein, the term "carrier" or "excipient" refers to any substance that is not itself a therapeutic agent, which acts as a carrier and / or diluent and / or adjuvant or vehicle for delivering a therapeutic agent to an individual, or any substance added to a formulation to improve its handling or storage characteristics, or to allow or facilitate formulation of dosage units of the composition into discrete preparations, such as capsules or tablets suitable for oral administration.

[0042] As used herein, the term "pharmaceutically acceptable" is defined herein to refer to those compounds, materials, compositions and / or dosage forms which are within the scope of sound medical judgment and are suitable for contact with the tissues of individuals (e.g., mammals or humans) without undue toxicity, irritation, allergic response, and other complications.

[0043] The compound TML-6 described herein is a curcumin derivative or a synthetic curcumin derivative with anti-inflammatory properties, which is involved in various mechanisms in the pathogenesis of AD, and reveals that the activity in reducing brain Aβ content is significantly better than curcumin and the anti-inflammatory effect is significantly better than curcumin. TML-6 can exist in the form of a pharmaceutically acceptable salt, solvate, hydrate or a prodrug thereof.

[0044] In some embodiments, the present disclosure provides a formulation comprising an amorphous or crystalline form of TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof and one or more excipients,

[0045]

[0046] In some embodiments, TML-6 is amorphous. Although not wishing to be bound by any theory, the applicant unexpectedly found that the amorphous form of TML-6 has improved solubility, dissolution and / or bioavailability. The amorphous form of TML-6 can be detected and measured by any known method, such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).

[0047] For example, the formulation may be characterized in that the differential scanning calorimetry thermogram does not include any sharp endothermic peaks, the DSC thermogram does not include an endothermic peak corresponding to crystalline TML-6 (about 132 ± 5 ° C), or the DSC thermogram includes a broad endothermic peak (e.g., about 50 ° C to about 90 ° C). In some embodiments, the broad endothermic peak may correspond to one or more excipients. In another aspect, the formulation may be characterized in that the X-ray powder diffraction (XRPD) pattern is substantially continuous (absence of sharp, narrow diffraction peaks), or the XRPD pattern does not include 2θ reflection angles (± 0.2° 2θ) of one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.

[0048] The particle size of the drug, TML-6 particle size, is controlled by drying and / or grinding / sieving (non-limiting examples are described below). Roller compaction and grinding / sieving can also be used to crush the particle size. In the present disclosure, at least 60% of the particle size distribution of TML-6 or its pharmaceutically acceptable salt, solvate, hydrate or prodrug in the formulation is less than 150 μm. The particle size distribution can be measured by sieving analysis, photon correlation spectroscopy or laser diffraction (International Standard ISO 13320-1), or electronic sensing zone, light obstruction, sedimentation or microscopy, which are well-known procedures to those skilled in the art.

[0049] To prepare the formulations described herein, one or more excipients are combined with TML-6 (and used together). The formulations described herein comprise about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 80% (w / w) of one or more excipients. In some embodiments, the formulation may comprise about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

[0050] One or more excipients include one or more copolymers based on polymethacrylate, copolymers based on poly(methacrylic acid), poloxamer and / or cellulose derivative excipients. Although it is not desired to be bound by any theory, it is believed that these excipients can increase the dissolution of TML-6 in gastric and / or intestinal fluids, control the solid form (preferably amorphous) of TML-6 and / or improve the PK profile of TML-6 formulations. Preferably, the amount of copolymers based on polymethacrylate is in the range of about 10% to about 70% (w / w) and the amount of cellulose derivative excipient is about 10% to about 70% (w / w). Copolymers based on polymethacrylate include copolymers based on poly(methyl methacrylate) (PMMA). Certain embodiments of copolymers based on PMMA include but are not limited to neutral, cationic and anionic forms of copolymers based on PMMA. In some embodiments, copolymers based on PMMA may include copolymers based on one or more of methyl methacrylate and methacrylic acid, methacrylate and acrylate. In another embodiment, PMMA is poly(methacrylic acid-co-methyl methacrylate). In some other embodiments, poly(methacrylic acid-co-methyl methacrylate) includes, but is not limited to, any of the methacrylic acid and methyl methacrylate based polymers described herein.

[0051] Certain embodiments of poly(methacrylic acid)-based copolymers include, but are not limited to, copolymers of methacrylic acid with methyl acrylate, ethyl acrylate, tert-butyl acrylate, methyl methacrylate, and N-isopropylacrylamide. In other embodiments, the poly(methacrylic acid)-based copolymer may be methacrylic acid-methyl methacrylate copolymer (1:1) and / or methacrylic acid-ethyl acrylate copolymer (1:1).

[0052] Certain examples of cellulose derivative excipients include, but are not limited to, cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropyl methylcellulose phthalate, microcrystalline cellulose (MCC), hydroxyethylcellulose, and hydroxypropyl methylcellulose.

[0053] In some embodiments, the polymethacrylate-based copolymers and / or poly(methacrylic acid)-based copolymers include poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2; polymers of methyl acrylate, methyl methacrylate, and methacrylic acid; poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate); 1:2:1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) ethyl acrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2, poly(ethyl acrylate, methyl methacrylate, methacrylate 2-trimethylammoniumethyl chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, methacrylate 2-trimethylammoniumethyl chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0. 1. Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate) 2:1 containing 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether), and poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether) and combinations thereof.

[0054] In some embodiments, the ratio of the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer to the cellulose-derived excipient is in the range of about 1:5 to about 5: 1. For example, the ratio of the poly(methacrylic acid)-based copolymer to the cellulose-derived excipient is in the range of about 1:5 to about 5: 1, such as 5:25, 6:24, 7:23, 8:22, 9:21, 10:20, 11:19, 12:18, 13:17, 14:16, 15:15, 16:14, 17:13, 18:12, 19:11, 20:10, 21:9, 22:8, 23:7, 24:6, or 25:5.

[0055] In some embodiments, one or more excipients include one or more polymeric materials, such as polysorbates and / or poloxamers. Certain embodiments of polysorbates include, but are not limited to, Tween 20, Tween 40, Tween 60, Tween 80, and Tween 85. Certain embodiments of poloxamers include, but are not limited to, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407. These polymeric materials can be used alone or in combination with one or more polymethacrylate-based copolymers and / or cellulose derivative excipients.

[0056] The formulations described herein can be prepared by ball milling, wet granulation, direct compression and dry granulation, hot melt extrusion or spray drying. In some embodiments, the formulations can be in the form of granules, spray-dried powders, capsules or tablets.

[0057] The formulations described herein may optionally be combined with one or more other excipients to form a pharmaceutical composition. In one embodiment, the pharmaceutical composition may be a tablet or a capsule. Certain embodiments of one or more other excipients include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.

[0058] Lubricants are typically added to prevent the tableting material from adhering to the punches, to minimize friction during tableting, and to allow the compressed tablet to be released from the die. Examples of pharmaceutically acceptable lubricants and pharmaceutically acceptable glidants include, but are not limited to, colloidal silicon dioxide, magnesium trisilicate, starch, talc, tricalcium phosphate, magnesium stearate, aluminum stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, powdered cellulose, and microcrystalline cellulose.

[0059] Binders are agents that impart cohesive qualities to powdered materials. Commonly used binders include starches and sugars, such as sucrose, glucose, dextrose, and lactose. Examples of pharmaceutically acceptable binders include, but are not limited to, starch; cellulose and its derivatives, such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxypropyl methyl cellulose; sucrose; dextrose; corn syrup; polysaccharides; and gelatin.

[0060] Diluents are added to increase the bulk weight of the blend to produce a practical compressed size. Examples of pharmaceutically acceptable fillers and pharmaceutically acceptable diluents include, but are not limited to, confectioners sugar, compressible sugar, dextrates, dextrins, dextrose, lactose, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, sucrose, and talc.

[0061] In order to ensure that the tablet has an acceptable disintegration rate, a disintegrant is generally included. Typical disintegrants include starch derivatives and salts of carboxymethylcellulose. Examples of pharmaceutically acceptable disintegrants include, but are not limited to, starch; clay; cellulose; alginates; gums; cross-linked polymers, such as cross-linked polyvinylpyrrolidone (PVP), cross-linked carboxymethylcellulose calcium and cross-linked carboxymethylcellulose sodium; soy polysaccharides; and guar gum.

[0062] Examples of glidants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, and sodium stearyl fumarate.

[0063] Other examples of suitable excipients are described in Handbook of pharmaceutical excipients, 3rd edition, edited by AH Kibbe, published by the American Pharmaceutical Association, Washington, DC, ISBN: 0-917330-96-X, or Handbook of Pharmaceutical Excipients (4th edition), edited by Raymond C Rowe - Publisher: Science and Practice.

[0064] The present disclosure also provides a method for preventing and / or treating neurodegenerative diseases, liver diseases, cancer, cardiovascular diseases, obesity, inflammatory diseases, or aging in a subject in need of such treatment, comprising administering to the subject a formulation or pharmaceutical composition described herein. The application of TML-6 in the treatment of these diseases can be seen in Min Hao, Yue Chu, Jingxuan Lei, Zhouhui Yao, Pingping Wang, Ziyan Chen, Kuilong Wang, Xianan Sang, Xin Han, LuWang, Gang Cao. Pharmacological Mechanisms and Clinical Applications of Curcumin: Update. Aging and disease. 2023, 14(3): 716-749 https: / / doi.org / 10.14336 / AD.2022.1101 and Su IJ, Chang HY, Wang HC, Tsai KJ. A Curcumin Analog Exhibits Multiple Biologic Effects on the Pathogenesis of Alzheimer's Disease and Improves Behavior, Inflammation, and β-Amyloid Accumulation in a Mouse Model. Int J Mol Sci. 2020 Jul 30;21(15):5459.doi:10.3390 / ijms21155459.PMID:32751716;PMCID:PMC7432838. Examples of neurodegenerative diseases include, but are not limited to, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, and prion disease.

[0065] The formulations and pharmaceutical compositions described herein have improved solubility and bioavailability and thus impart advantageous efficacy in preventing and / or treating neurodegenerative diseases.

[0066] In order to assist those skilled in the art in practicing the present invention, the following examples / studies are provided.

[0067] Preparation of formulations of the present disclosure: wet granulation

[0068] For the formulations of Examples 1 to 3 (E01 to E03), the components listed in Table 1 were sieved and mixed to form granules, and then dried and shaped to form formulation products. In Table 1, TPGS is the abbreviation of D-α-Tocopherol polyethylene glycol-1000 succinate, and SDS (also known as SLS) is the abbreviation of sodium dodecyl sulfate.

[0069] Table 1: Components of formulations (E01 to E03).

[0070]

[0071]

[0072] Preparation of formulations of the present disclosure: Solvent evaporation solid dispersion

[0073] For the formulations of Examples 4 to 12 (E04 to E12), the components listed in Table 2 were dispersed in a solvent (purified water, 95% ethanol and / or acetone), and the resulting dispersion was dried in an oven. After cooling, the dry dispersion was ground and sieved.

[0074] Table 2: Components of formulations (E04 to E12).

[0075]

[0076] Preparation of the formulations of the present disclosure: spray drying

[0077] The components of the formulation of Example 13 (E13) are shown in Table 3.

[0078] Table 3: Components of formulation (E13).

[0079] API TML-6, 10.5g polymer Methacrylic acid-ethyl acrylate copolymer (1:1) 19.5g Solvents Acetone / EtOH=95 / 5v / v%1500mL Ratio: API / Polymer 35 / 65w / w%, solid concentration in solvent: 2%

[0080] The above components are mixed and the resulting mixture is sprayed using a spray dryer, and then the spray-dried powder is collected.

[0081] The formulations of Examples 14 to 17 (E14 to E17) were prepared using the same spray drying method and their components are shown in Table 4.

[0082] Table 4: Components of formulations (E13 to E17).

[0083] Components (wt%) E13 E14 E15 E16 E17 TML-6 35 70 80 70 70 Poly(methacrylic acid-co-ethyl acrylate) 1:1 65 30 20 10 HPMC 20 30

[0084] X-ray powder diffraction (XRPD) studies

[0085] TML-6 (unformulated) and TML-6 formulation E13 were analyzed on the zero background sample holder and submitted to X-ray analysis. The XRPD pattern of TML-6 ( Figure 1 ) shows 2θ reflection angles (±0.2° 2θ) such as 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°, and the reflection angles represent the crystalline state.

[0086] XRPD pattern of TML-6 Formulation E13 ( Figure 4 ) is essentially continuous, without any sharp, narrow diffraction peaks, which indicates an amorphous form.

[0087] Differential Scanning Calorimetry (DSC) Studies

[0088] The sample (1-2 mg) was accurately weighed and placed in an aluminum pan, which was sealed and heated from 40°C to 160°C at a heating ramp rate of 10°C / min for DSC analysis.

[0089] DSC thermogram of TML-6 ( Figure 3 ) is characterized by a sharp endothermic peak at 134.25 °C, which corresponds to its melting point in the crystalline state.

[0090] DSC thermograms of TML-6 formulations E14 to E17 ( Figure 3 ) shows a broad peak at about 50°C to about 90°C, which corresponds to the melting point of the excipient (which may be offset), and does not show the characteristic peak of crystalline TML-6.

[0091] DSC melting points of TML-6 formulations E10 and E12 ( Figure 5 ) shows no significant exothermic or endothermic peaks, which also indicates an amorphous form.

[0092] DSC thermogram of TML-6 formulation E04 ( Figure 4 ) shows an endothermic peak at 132.55°C, close to that of TML-6 (about 132.85°C), which indicates a crystalline state.

[0093] Dissolution tests in 0.1 HCl and pH 6.8 phosphate buffer, 30 min

[0094] The dissolution of TML-6 (API alone) and TML-6 formulations (E01 to E12) in a medium simulated gastric fluid during 30 minutes was measured, and the results are shown in Tables 5 and 6. The dissolution of TML-6 (API alone) and TML-6 formulations (E13 to E17) in a medium simulated intestinal fluid was measured during 30 minutes, and the results are shown in Table 6.

[0095] Table 5: Dissolution of TML-6 formulations (E01 to E12)

[0096]

[0097]

[0098] Table 6: Dissolution of TML-6 formulations (E13 to E17)

[0099]

[0100] Referring to Tables 5 and 6 above, the addition of polymethacrylate-based copolymers, poly(methacrylic acid)-based copolymers, poloxamer and / or cellulose derivative excipients can effectively improve the dissolution of TML-6. In addition, the amorphous form of TML-6 shows improved dissolution compared to the crystalline form.

[0101] Pharmacokinetic (PK) studies in rats

[0102] The goal of this study is to obtain the pharmacokinetic profile of TML-6 API (unformulated, crystalline), TML-6 formulation E02 (crystalline), TML-6 formulation E10, E12 and E13 (amorphous) when administered to 6-8 week old male Sprague-Dawley rats (BioLASCO Taiwan Co., Ltd.) at oral (PO) doses. Five doses were used for rats. Animals received a single dose of 25 mg / kg of TML-6 API, TML-6 formulations E02, E10, E12 and E13 via oral gavage.

[0103] Preparation of dosing solutions: TML-6 API, E02, E10, E12 and E13 oral formulations were prepared by suspending these TML6 formulation powders in an aqueous vehicle composed of 0.5% methylcellulose (MC) to a concentration of 2.5 mg / mL TML-6.

[0104] Blood samples for plasma sample preparation and bioanalysis series were collected from all animals via the tail vein. Approximately 0.2 mL of blood samples were collected at the following time points: before dosing and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after dosing. After blood sampling, plasma fractions were prepared by centrifugation (1,000 × g, 15 minutes, at 4°C). TML-6 concentrations in rat plasma were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS), as shown in Table 1. Figure 6 and 7The lower limit of quantitation (LLOQ) was 0.1 ng / mL. The plasma concentration-time data above the LLOQ at various dose levels were used to calculate the PK parameters of TML-6 (Table 7).

[0105] Results: PK studies were performed on TML-6 API and TML-6 formulations E02, E10, E12, and E13 after oral administration of 25 mg / kg in 0.5% MC suspension to rats. max and AUC (0-∞) The results are summarized in Table 7. The difference between unformulated TML-6 (TML-6 API) and TML-6 formulation E02 in C max and AUC (0-∞) There was no significant difference in the TML-6 formulations E10, E12 and E13. max and AUC (0-∞) The results also showed that the dissolution-improved formulations of TML-6 also had improved C max and AUC (0-∞) .

[0106] Table 7: TML-6C in rats after oral dosing max and AUC (0-∞) Overview of .

[0107] way Solid form Dosage (mg / kg) <![CDATA[C max (ng / mL)]]> <![CDATA[AUC (0-∞) (ng*hr / mL)]]> Separate API PO crystallization 25.0 25.3 73.6 E02 PO crystallization 25.0 19.8 82.9 E10 PO Amorphous 25.0 142 256 E12 PO Amorphous 25.0 144 250 E13 PO Amorphous 25.0 178 267

[0108] The compositions and methods of the present disclosure each have several innovative aspects, no single aspect of which is solely responsible or necessary for obtaining the desirable properties disclosed herein. The various features and processes described above can be used independently or combined in various ways. All possible combinations and sub-combinations are within the scope of the present disclosure. Various modifications to the embodiments described in the present disclosure may be readily apparent to a skilled person, and the general principles defined herein may be applied to other embodiments without departing from the spirit or scope of the present disclosure. Therefore, the present application is not intended to be limited to the embodiments shown herein, but should be given the broadest scope consistent with the present disclosure, principles, and new features disclosed herein.

[0109] Certain features described in this specification may also be implemented in combination in the context of separate embodiments. Conversely, various features describing a single embodiment may also be implemented separately in multiple embodiments, or in any suitable sub-combination. In addition, although the above features may be described as working in certain combinations, or even initially required as such combinations, in some cases one or more features may be deleted from the required combination, and the required combination may be directed to a sub-combination or variation of a sub-combination. No single feature or group of features is necessary or indispensable for every embodiment.

Claims

1. A formulation comprising amorphous TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and one or more excipients, 2. The formulation according to claim 1, characterized in that The differential scanning calorimetry thermogram did not contain any sharp endothermic peaks.

3. The formulation according to claim 1 or 2, characterized in that The DSC thermogram does not contain an endothermic peak corresponding to crystalline TML-6.

4. The formulation according to any one of claims 1 to 3, characterized in that The DSC thermogram comprises a broad endothermic peak at about 50°C to about 90°C.

5. The formulation according to claim 1, characterized in that The X-ray powder diffraction (XRPD) pattern is essentially continuous, without any sharp, narrow diffraction peaks.

6. The formulation according to claim 5, characterized in that The XRPD pattern does not include 2θ reflection angle numbers (±0.2° 2θ) of one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.

7. A formulation comprising about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 80% (w / w) of one or more excipients, 8. The formulation according to claim 7, wherein the TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof is in an amorphous form.

9. The formulation according to claim 7 or 8, comprising about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and about 10% (w / w) to about 30% (w / w) of one or more excipients.

10. The formulation of any one of claims 7 to 9, wherein the one or more excipients comprises an enteric polymer.

11. The formulation of any one of claims 7 to 10, wherein the one or more excipients comprise at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer and / or a cellulose derivative excipient.

12. The formulation of claim 11, wherein the ratio of the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer relative to the cellulose derivative excipient is in the range of about 1:5 to about 5:

1.

13. The formulation according to claim 11 or 12, wherein the amount of the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer is in the range of about 10% to about 70% (w / w), and the amount of the cellulose derivative excipient is in the range of about 10% to about 70% (w / w).

14. The formulation according to any one of claims 11 to 13, wherein the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer is selected from the group consisting of: poly(methacrylic acid, methyl methacrylate) 1:1, poly(methacrylic acid, ethyl acrylate) 1:1, poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:2; polymers of methyl acrylate, methyl methacrylate and methacrylic acid; poly(butyl methacrylate-co-methacrylic acid (2-dimethacrylate); 1:2:0.2; Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2; Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2; Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.2; Poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) acyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammoniumethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethane ammonium chloride) 1:2:0.1, poly(ethyl acrylate, methyl methacrylate) 2:1 containing 0.7% (PEG stearyl ether), poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether) and poly(ethyl acrylate, methyl methacrylate) 2:1 containing 1.5% (nonoxynol ether) and combinations thereof.

15. The formulation of any one of claims 7 to 14, wherein the cellulose derivative excipient is selected from the group consisting of cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, cellulose ester derivatives, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropyl methylcellulose phthalate, microcrystalline cellulose, hydroxyethylcellulose and hydroxypropyl methylcellulose.

16. The formulation according to any one of claims 7 to 25, wherein the formulation is in the form of a tablet, granules, capsule or spray-dried powder.

17. A pharmaceutical composition comprising a formulation according to any one of claims 1 to 16 and one or more additional excipients.

18. The pharmaceutical composition of claim 17, wherein the one or more additional excipients include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.

19. A method for preventing and / or treating a neurodegenerative disease, liver disease, cancer, cardiovascular disease, obesity, inflammatory disease or aging in a subject in need of such treatment, comprising administering to the subject a formulation according to any one of claims 1 to 21 or a pharmaceutical composition according to claim 17 or 18.

20. The method of claim 19, wherein the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, or a prion disease.